tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chris Shibutani, 116 are a BUY (56.31%), 82 are a HOLD (39.81%), 8 are a SELL (3.88%).
Analyst Chris Shibutani, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 59.5% that have a potential upside of 25.39% achieved within 232 days.
Chris Shibutani’s has documented 392 price targets and ratings displayed on 39 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 02-Jun-2026.
Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $117 was fulfilled within 1 day with a profit of $21.2 (22.13%) receiving and performance score of 221.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 18-Mar-2024
$58
$9.01 (18.39%)
$41
6 days ago
(29-Jul-2026)
4/5 (80%)
$9.66 (19.98%)
603
Hold Since 06-Dec-2022
$61
$12.01 (24.52%)
$60
6 days ago
(29-Jul-2026)
9/11 (81.82%)
$12.66 (26.19%)
123
Buy Since 19-Dec-2022
$65
$16.01 (32.68%)
$43
7 days ago
(28-Jul-2026)
17/18 (94.44%)
$14.5 (28.71%)
408
Buy Since 01-May-2025
$63
$14.01 (28.60%)
$42
15 days ago
(20-Jul-2026)
29/34 (85.29%)
$11.28 (21.81%)
353
Buy Since 28-May-2025
$62
$13.01 (26.56%)
$61
22 days ago
(13-Jul-2026)
6/8 (75%)
$10.13 (19.53%)
223
Which stock is Chris Shibutani is most bullish on?
What Year was the first public recommendation made by Chris Shibutani?
